NMC
IRWD icon

Nine Masts Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Nine Masts Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.5K Buy
+13,527
New +$55.4K 0.01% 145

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nine Masts Capital's IRWD Position: Q1 2026 in Review

Nine Masts Capital opened a new position in Ironwood Pharmaceuticals (IRWD) in Q1 2026: 13,527 shares worth $47.5K. The stake represents 0.01% of the portfolio and ranks #145 among its holdings.

226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Nine Masts Capital held 13,527 shares of Ironwood Pharmaceuticals worth $47.5K as of Q1 2026.
  • Ironwood Pharmaceuticals was a new Nine Masts Capital position in Q1 2026.
  • Ironwood Pharmaceuticals made up 0.01% of Nine Masts Capital's portfolio in Q1 2026, its #145 holding.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.